Audio

In diabetic macular edema, senescent cells build up in the retina, leading to vision loss. A new drug forces these undead cells to die, healing the retina.

Actinium-225 is a radioactive isotope that kills cancer cells with a burst of alpha particles, but it was difficult to make enough of it — until now.

An off-the-cuff request at the local butcher led to a serendipitous discovery about heart valve disease, leading to potential new sex-specific ways to treat it.

Researchers discovered a new gene required for pancreas development, but much to their surprise, they found that it was absent in all animals except primates.

With some out-of-the-box engineering, researchers have developed a nature-inspired strategy to turn sugar in packaged foods into gut-healthy fiber.

Spaceflight Associated Neuro-ocular Syndrome impairs astronauts’ vision, but new strategies to study the condition in space and on Earth may lead to treatments.

Chagas disease stems from a parasitic infection. Now, with the help of a few insect-eating monkeys, a new treatment for this condition is on the horizon.

People with misophonia feel intense anger in response to certain sounds. Can scientists find a cure?

Bacterial contaminants in cell cultures pose a significant threat to the biopharmaceutical safety. How do scientists detect these hard-to-spot pests?

On a quest to bring new a new hemophilia gene therapy to the clinic, one research team leapt over hurdle after hurdle to produce enough viral therapeutics to treat a large number of patients.

Biobanking unearths samples that have been long lost in the backs of freezers and scientific information buried in dusty notebooks to make ground breaking discoveries for human health.

Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.

John Moffat, a senior scientist in Biochemical and Cellular Pharmacology at Genentech, discusses the target validation and prioritization opportunities revealed at the crossroads of target-focused and phenotypic profiling approaches.

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.

Mica Zaragoza, Consultant, Global Custom Manufacturing & OEM Solutions, Promega Corporation, discusses the company's standard and custom product development and consultative services associated with biotechnology and molecular biology research and drug discovery.

Dr. George Karlin-Neuman, Director of Scientific Affairs with the Bio-Rad Digital Biology Center in Pleasanton, California.

The costs of doing business (badly)